ArticleBritish journal of cancer2009
Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas.
Article in British journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2013Guideline
- Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Archives of pathology & laboratory medicine · 2013Guideline
- Pleomorphic adenoma: does the immunohistochemical profile direct the clinical profile: retrospective study and review of literature.BMC cancer · 2026Review
- Case Report: Treatment of an unresectable mucoepidermoid carcinoma with osimertinib.Frontiers in oncology · 2026Article
- A Comprehensive Review of Advances in Molecular Mechanisms and Targeted Therapies for the Specific Type of Cystic Lung Cancer.OncoTargets and therapy · 2025Review
- Establishment of a patient-derived mucoepidermoid carcinoma cell line with theMolecular and clinical oncology · 2022Article
- Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma.Oral oncology · 2021Article
- Genomics of mucoepidermoid and adenoid cystic carcinomas.Laryngoscope investigative otolaryngology · 2018Review
- Autocrine epiregulin activates EGFR pathway for lung metastasis via EMT in salivary adenoid cystic carcinoma.Oncotarget · 2016Article
- Molecular Pathology and Biomarkers.Advances in oto-rhino-laryngology · 2016Review
- Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.Diagnostic pathology · 2015Article
- Primary adenoid cystic carcinoma of the lung: Clinicopathological features, treatment and results.Oncology letters · 2015Article
- Salivary gland carcinomas.Oral and maxillofacial surgery · 2012Review
- EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas.Virchows Archiv : an international journal of pathology · 2012Article
- EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma.Journal of cancer research and clinical oncology · 2012Article
- Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands.British journal of cancer · 2010Article
- No incidence of BRAF mutations in salivary gland carcinomas--implications for anti-EGFR therapies.Journal of biomedicine & biotechnology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activating mutations within the epidermal growth factor (EGFR) tyrosine kinase domain identify non-small cell lung cancer patients with improved clinical response to tyrosine kinase inhibitor therapy. Recently, we identified two EGFR mutations in a cohort of 25 salivary gland carcinomas (SGCs) by screening the tumour samples for the both most common hotspot mutations in exons 19 and 21 by allele-specific PCR. Here, we present a comprehensive sequencing analysis of the entire critical EGFR tyrosine kinase domain in 65 SGC of the main histopathological types. We found EGFR mutations in the tyrosine kinase domain to be a rare event in SGCs. No additional mutations other than the two known exon 19 deletions (c.2235_2249del15) in a mucoepidermoid carcinoma and an adenoid cystic carcinoma have been detected. Other putative predictive markers for EGFR-targeted therapy in SGCs might be relevant and should be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.